Bibliografisk noteFunding Information:
Conflict of Interest Disclosures: None of the authors have any interests (commercial or otherwise) in Medaval. Dr Picone reported having served as a consultant on BP device validation for HEARTS in the Americas, an initiative of the Pan American Health Organization, and that he is supported by a postdoctoral fellowship (104774) from the National Heart Foundation of Australia. Dr Campbell reported receiving personal fees from Resolve to Save Lives, the World Health Organization, the Pan American Health Organization, and the World Bank and being a special advisor to the World Hypertension League Board. Dr Schutte reported receiving speaker honoraria from Omron, Servier, Sanofi, Takeda, Novartis, Sun Pharmaceuticals, and Abbott and serving as a consultant on BP device validation for HEARTS in the Americas. Dr Olsen reported receiving personal fees from Astra Zeneca. Dr Sharman reported having served as a consultant on BP device validation for HEARTS in the Americas and being principal investigator of a National Health and Medical Research Council partnership grant (S0026615) on cardiovascular disease risk assessment; among the partners listed on that grant is Uscom Limited, a medical technology company that manufactures a central BP monitor. No other disclosures were reported.
Conflict of Interest Disclosures: Dr Davis reported receiving grants from the National Institutes of Health outside the submitted work. No other disclosures were reported.
Funding/Support: The study was supported by the National Institute on Alcohol Abuse and Alcoholism (grant R01AA029831), the National Institute on Aging (grants AG057557, AG061388, and AG062272), the National Institute on Drug Abuse (grant UG1DA049435), the National Cancer Institute (grant R25CA221718), and the Clinical and Translational Science Collaborative of Cleveland (grant 1UL1TR002548-01).